<DOC>
	<DOCNO>NCT00606112</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerance single intravenous ( vein ) dose trodusquemine ( MSI-1436 ) obese , type 2 diabetic . Different amount trodusquemine ( MSI-1436 ) give volunteer group throughout study . Another purpose evaluate pharmacokinetics ( PK - study way drug enters leave blood tissue time ) trodusquemine ( MSI-1436 ) . Finally , study also determine whether trodusquemine ( MSI-1436 ) effect appetite , mood behavior , selective biomarkers ( substance blood may change response study drug ) .</brief_summary>
	<brief_title>A Single Dose , Tolerance Pharmacokinetic Study Obese Overweight Type 2 Diabetic Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1. male female obese overweight type 2 diabetic subject , 18 55 year old ( inclusive ) 2. either treatment naive inadequately control either metformin alone metformin combination sulfonylurea . Subjects metformin combination sulfonylurea allow 2 week period wash sulfonylurea dosing . 3. fast blood sugar ≥ 100 mg/dL , hemoglobin A1C ≥ 7.5 % ( ≤ 11.0 % ) . Subjects combination metformin sulfonylurea must hemoglobin A1C ≥ 7.5 % ( ≤ 10.0 % ) ; 4. nonsmoker 5. body mass index ( BMI ) 2740 kg/m2 1. likely allergy sensitivity component Trodusquemine ( MSI1436 ) Injection base know allergy drug class ; 2. subject history allergy ( rash , hive , breathe difficulty , etc . ) medication , either prescription nonprescription , include dietary supplement herbal medication ; 3. subject history severe allergy bronchial asthma ; 4. clinically significant history current abnormality disease organ system , include renal , hepatic , gastrointestinal , cardiovascular ( except hyperlipidemia control hypertension ) , pulmonary ( include chronic asthma ) , endocrine ( except diabetes ) , central nervous , hematologic system , recent clinically significant surgery ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>